ES2640009T3 - Composiciones para aliviar los síntomas del síndrome premenstrual - Google Patents
Composiciones para aliviar los síntomas del síndrome premenstrual Download PDFInfo
- Publication number
- ES2640009T3 ES2640009T3 ES10154498.9T ES10154498T ES2640009T3 ES 2640009 T3 ES2640009 T3 ES 2640009T3 ES 10154498 T ES10154498 T ES 10154498T ES 2640009 T3 ES2640009 T3 ES 2640009T3
- Authority
- ES
- Spain
- Prior art keywords
- lecithin
- pharmaceutical
- phospholipase
- serine
- pms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 37
- 208000024891 symptom Diseases 0.000 title claims abstract description 33
- 206010036618 Premenstrual syndrome Diseases 0.000 title abstract description 5
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract description 39
- 235000010445 lecithin Nutrition 0.000 claims abstract description 38
- 239000000787 lecithin Substances 0.000 claims abstract description 38
- 229940067606 lecithin Drugs 0.000 claims abstract description 38
- 229960001153 serine Drugs 0.000 claims abstract description 31
- 235000016709 nutrition Nutrition 0.000 claims abstract description 16
- 239000002994 raw material Substances 0.000 claims abstract description 14
- 235000013311 vegetables Nutrition 0.000 claims abstract description 13
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 claims abstract description 9
- 235000013336 milk Nutrition 0.000 claims abstract description 8
- 239000008267 milk Substances 0.000 claims abstract description 8
- 210000004080 milk Anatomy 0.000 claims abstract description 8
- 206010019233 Headaches Diseases 0.000 claims abstract description 7
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 7
- 229930195729 fatty acid Natural products 0.000 claims abstract description 7
- 239000000194 fatty acid Substances 0.000 claims abstract description 7
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 7
- 231100000869 headache Toxicity 0.000 claims abstract description 7
- 206010000060 Abdominal distension Diseases 0.000 claims abstract description 5
- 208000002874 Acne Vulgaris Diseases 0.000 claims abstract description 5
- 208000006820 Arthralgia Diseases 0.000 claims abstract description 5
- 206010010774 Constipation Diseases 0.000 claims abstract description 5
- 206010012735 Diarrhoea Diseases 0.000 claims abstract description 5
- 206010056465 Food craving Diseases 0.000 claims abstract description 5
- 206010000059 abdominal discomfort Diseases 0.000 claims abstract description 5
- 206010000496 acne Diseases 0.000 claims abstract description 5
- 230000004594 appetite change Effects 0.000 claims abstract description 5
- 208000024330 bloating Diseases 0.000 claims abstract description 5
- 239000004615 ingredient Substances 0.000 claims abstract description 5
- 208000000112 Myalgia Diseases 0.000 claims abstract description 4
- 208000013465 muscle pain Diseases 0.000 claims abstract description 4
- 150000003839 salts Chemical class 0.000 claims abstract description 4
- 206010006313 Breast tenderness Diseases 0.000 claims abstract description 3
- 208000016255 tiredness Diseases 0.000 claims abstract description 3
- 230000003867 tiredness Effects 0.000 claims abstract description 3
- 206010006262 Breast inflammation Diseases 0.000 claims abstract 2
- 230000003187 abdominal effect Effects 0.000 claims abstract 2
- 208000004396 mastitis Diseases 0.000 claims abstract 2
- 102000011420 Phospholipase D Human genes 0.000 claims description 23
- 108090000553 Phospholipase D Proteins 0.000 claims description 23
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 claims description 11
- 239000008347 soybean phospholipid Substances 0.000 claims description 10
- 230000001580 bacterial effect Effects 0.000 claims description 6
- 238000006911 enzymatic reaction Methods 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 240000002791 Brassica napus Species 0.000 claims description 4
- 235000004977 Brassica sinapistrum Nutrition 0.000 claims description 4
- 241000196324 Embryophyta Species 0.000 claims description 4
- 229940005741 sunflower lecithin Drugs 0.000 claims description 4
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 2
- 150000004671 saturated fatty acids Chemical class 0.000 claims 1
- 235000003441 saturated fatty acids Nutrition 0.000 claims 1
- 206010022437 insomnia Diseases 0.000 abstract description 4
- 238000000034 method Methods 0.000 description 16
- 238000011282 treatment Methods 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 9
- 230000005906 menstruation Effects 0.000 description 9
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 6
- 241000237536 Mytilus edulis Species 0.000 description 6
- 235000020638 mussel Nutrition 0.000 description 6
- 230000002255 enzymatic effect Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 4
- 150000003904 phospholipids Chemical class 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 235000013365 dairy product Nutrition 0.000 description 3
- 208000008035 Back Pain Diseases 0.000 description 2
- 240000007124 Brassica oleracea Species 0.000 description 2
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 2
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 2
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010050819 Musculoskeletal chest pain Diseases 0.000 description 2
- 206010042674 Swelling Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- -1 lysophospholipids Chemical class 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 230000027758 ovulation cycle Effects 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- ZPDQFUYPBVXUKS-YADHBBJMSA-N 1-stearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)COP(O)(=O)OC[C@H](N)C(O)=O ZPDQFUYPBVXUKS-YADHBBJMSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical group NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- 241000186046 Actinomyces Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000009862 primary prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000003248 quinolines Chemical group 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000009863 secondary prevention Effects 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000005186 women's health Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US606975 | 2009-10-27 | ||
| US12/606,975 US8399432B2 (en) | 2009-10-27 | 2009-10-27 | Compositions and methods of treatment for alleviating premenstrual syndrome symptoms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2640009T3 true ES2640009T3 (es) | 2017-10-31 |
Family
ID=43610927
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10154498.9T Active ES2640009T3 (es) | 2009-10-27 | 2010-02-24 | Composiciones para aliviar los síntomas del síndrome premenstrual |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US8399432B2 (https=) |
| EP (1) | EP2322184B1 (https=) |
| JP (2) | JP2011093881A (https=) |
| DK (1) | DK2322184T3 (https=) |
| ES (1) | ES2640009T3 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2769725T3 (en) | 2013-02-22 | 2016-08-22 | Lipogen Ltd | PREPARATIONS FOR USE AT relief of symptoms associated with premenstrual syndrome and premenstrual dysphoric disorder |
| WO2018057737A1 (en) | 2016-09-22 | 2018-03-29 | Cash Alan B | Method to alleviate the symptoms of pms |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3791951B2 (ja) | 1995-11-08 | 2006-06-28 | 株式会社ヤクルト本社 | 多価不飽和脂肪酸含有ホスファチジルセリンを含む油脂組成物の製造方法 |
| CA2382580C (en) * | 1999-08-31 | 2009-05-19 | Jenapharm Gmbh & Co. Kg | Mesoprogestins (progesterone receptor modulators) for the treatment and prevention of benign hormone dependent gynecological disorders |
| JP2002029967A (ja) * | 2000-02-02 | 2002-01-29 | Nisshin Oil Mills Ltd:The | 月経前症候群症状緩和用食用油脂組成物 |
| US7208180B2 (en) * | 2000-05-08 | 2007-04-24 | N.V. Nutricia | Method and preparation for the preventing and/or treating vascular disorders and secondary disorders associated therewith |
| JP2002302441A (ja) * | 2001-02-02 | 2002-10-18 | Nisshin Oil Mills Ltd:The | 月経前症候群症状緩和用組成物及び飲食物 |
| JP2003055216A (ja) * | 2001-08-03 | 2003-02-26 | Nisshin Oillio Ltd | 月経中症状緩和剤及びそれを含有する飲食物 |
| NZ591627A (en) | 2001-12-05 | 2012-09-28 | Teva Womens Health Inc | Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology |
| US6939877B2 (en) | 2002-09-12 | 2005-09-06 | Wyeth | Antidepressant piperidine derivatives of heterocycle-fused benzodioxans |
| IL158139A0 (en) * | 2003-09-25 | 2004-09-27 | Enzymotec Ltd | Stabilized formulations of phosphatidyl serine |
| WO2005044176A2 (en) * | 2003-11-10 | 2005-05-19 | Lipogen Ltd. | Compositions containing phosphatidic acid, methods of use thereof, methods of manufacture thereof, and articles of manufacture containing same |
| US20050196434A1 (en) * | 2004-03-04 | 2005-09-08 | Brierre Barbara T. | Pharmaceutical composition and method for the transdermal delivery of magnesium |
| JP2005263668A (ja) * | 2004-03-17 | 2005-09-29 | Nof Corp | ホスファチジルセリン含有水性組成物及び用途 |
| JP2006131572A (ja) * | 2004-11-08 | 2006-05-25 | Tomiyoshi Murakawa | 月経関連症状の緩和剤 |
| JP2006131571A (ja) * | 2004-11-08 | 2006-05-25 | Nakai Kosan:Kk | 月経関連症状の緩和剤 |
| US8846338B2 (en) * | 2008-08-07 | 2014-09-30 | Lipogen Ltd. | Processes for the preparation of phosphatides |
-
2009
- 2009-10-27 US US12/606,975 patent/US8399432B2/en active Active
-
2010
- 2010-02-24 EP EP10154498.9A patent/EP2322184B1/en active Active
- 2010-02-24 DK DK10154498.9T patent/DK2322184T3/en active
- 2010-02-24 ES ES10154498.9T patent/ES2640009T3/es active Active
- 2010-08-02 JP JP2010173298A patent/JP2011093881A/ja not_active Withdrawn
-
2014
- 2014-12-19 JP JP2014258058A patent/JP5840284B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US8399432B2 (en) | 2013-03-19 |
| US20110098249A1 (en) | 2011-04-28 |
| JP2011093881A (ja) | 2011-05-12 |
| JP5840284B2 (ja) | 2016-01-06 |
| JP2015057441A (ja) | 2015-03-26 |
| EP2322184A1 (en) | 2011-05-18 |
| EP2322184B1 (en) | 2017-06-21 |
| DK2322184T3 (en) | 2017-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8877239B2 (en) | Lipid supplements for maintaining health and treatment of acute and chronic disorders | |
| ES2369074T3 (es) | Composiciones que tienen efectos preventivos o mejoradores de síntomas o enfermedades provocados por una hipofunción cerebral. | |
| ES2309021T3 (es) | Fosfatidil-l-serina y acido fosfatidico para tratar la depresion y aliviar el estres. | |
| US11066432B2 (en) | Ether phospholipids and method for producing the same | |
| BRPI0818723B1 (pt) | Composição para nutrição infantil | |
| JP6207545B2 (ja) | 学習記憶能力増強剤 | |
| US9717734B2 (en) | Chewable lipid supplements containing caffeine for increasing alertness, focus and energy | |
| ES2640009T3 (es) | Composiciones para aliviar los síntomas del síndrome premenstrual | |
| KR20120051458A (ko) | 크릴 인지질을 이용하여 아스타잔틴 및 ｄｈａ－ 및/또는 ｅｐａ－결합된 포스파티딜세린을 함유한 조성물을 제조하는 방법 및 이러한 방법에 의해 제조된 조성물 | |
| JP2016029096A (ja) | 健康の維持ならびに急性および慢性障害の治療のための脂質サプリメントを含有するチュアブルウエハース | |
| US11253531B2 (en) | Lipid supplements for reducing nerve action potentials | |
| CN109153693A (zh) | 安全－稳定的缩醛磷脂和其制剂及认知症的未病状态的判断方法 | |
| US10874681B2 (en) | Oral lipid supplements for treating pain and fibromyalgia | |
| JP6842093B2 (ja) | 学習記憶能力増強剤 | |
| JP2017165785A (ja) | 学習記憶能力増強剤 | |
| CN107648208A (zh) | 一种具有保肝功效的中药组合物及其应用和由其制成的注射液 | |
| HK40008021A (en) | Safe and stable plasmalogen, formulation thereof, and method for assessing presymptomatic state of dementia |